What Relievant Medsystems does

Relievant Medsystems is a U.S. medical device company founded in 2006 and headquartered in Edina, Minnesota, that develops and commercializes the Intracept Procedure (Intracept Intraosseous Nerve Ablation System), an FDA-cleared, one-time minimally invasive outpatient treatment for chronic vertebrogenic low back pain. The procedure uses targeted radiofrequency energy to ablate the basivertebral nerve within the vertebral body, interrupting pain signal transmission; the nerve has not demonstrated capacity to regenerate, which supports durable clinical outcomes (75% of patients report sustained improvement at 5 years, per Fischgrund et al., 2020). The product is a single-procedure offering with no platform-plus-modules architecture, and the company's offerings are limited to the ablation system and supporting physician-training infrastructure.

The company commercializes the procedure through a trained-physician specialist network, employing an enterprise field sales motion that targets pain management clinicians and healthcare provider sites; patients are routed to trained physicians via a find-a-doctor locator on the patient-facing intracept.com site. Marketing channels center on patient education content, a patient ambassador program, and an insurance coverage finder tool. Indication is narrowly defined: patients with chronic low back pain of at least six months, prior conservative care of at least six months, and MRI features consistent with Modic changes.

Relievant was a venture capital-backed private company that raised approximately $240 million across multiple rounds from a syndicate including New Enterprise Associates, Canaan Partners, Endeavour Vision, Vensana Capital, Lightstone Ventures, Morgenthaler Ventures, and Ally Bridge Group. In January 2026 the company was acquired by Boston Scientific Corporation and integrated into its Neuromodulation segment, which reported mid-teens pain management growth partly attributable to Relievant contributions. The company's operating geography is the United States, and the Intracept brand continues to be marketed under the Boston Scientific portfolio.

Name

Relievant Medsystems

Legal name

Relievant MedSystems, Inc.

Website

https://relievant.com

Company type

Private

Founded year

2006

Operating status

Acquired

Headcount range

11–50 employees

Short description

Relievant Medsystems develops and commercializes the Intracept Procedure, an FDA-cleared minimally invasive radiofrequency ablation of the basivertebral nerve for chronic vertebrogenic low back pain, distributed through a trained physician network in the United States.

Ownership category

akta.pro rank

Product category

Minimally invasive spine medical devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)

akta.pro secondary industry

Pain Management (Spine & Musculoskeletal) (HLAKALAM)

Keywords

• Chronic pain treatment
• Minimally invasive procedures
• Radiofrequency ablation
• Spine medical devices
• Intraosseous nerve ablation

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations

Revenue model

1. Intracept Procedure Commercialization: Relievant Medsystems generates revenue through commercialization of its FDA-cleared Intracept Procedure for treating chronic vertebrogenic low back pain. The company has raised $240 million in total funding to support commercialization efforts, with Boston Scientific acquiring the company in 2026.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Relievant Medsystems developed and commercialized the Intracept Procedure, a one-time, minimally invasive, outpatient treatment that uses targeted radiofrequency energy to ablate (heat) the basivertebral nerve within vertebrae to stop chronic vertebrogenic low back pain signals. The procedure is drug-free, implant-free, FDA-cleared, takes 60-90 minutes, and is supported by purpose-built surgical tools and 15+ years of clinical evidence.

Product overview

Relievant Medsystems offers a single core product: the Intracept Procedure (also known as the Intracept™ Intraosseous Nerve Ablation System). This is a one-time, minimally invasive outpatient procedure that uses targeted radiofrequency ablation to treat chronic vertebrogenic low back pain by deactivating the basivertebral nerve. The company does not operate a platform-plus-modules architecture; its offering consists of this single FDA-cleared procedure.

Differentiator

Problem solved

Functional benefit

Products and services

• Intracept Procedure (Intracept Intraosseous Nerve Ablation System) A one-time, minimally invasive, outpatient procedure that uses targeted radiofrequency energy to ablate (heat) the basivertebral nerve within the vertebrae to stop pain signal transmission to the brain, providing long-term relief for chronic vertebrogenic low back pain in adult patients with Modic changes on MRI who have failed at least 6 months of conservative care. The procedure is drug-free, implant-free, takes 60-90 minutes, and provides 5+ years of pain relief. It is sold to and performed by trained pain management physicians and interventional spine specialists in the U.S.

Quantifiable outcome

• 75% of patients still experience improvements in pain and daily activities after 5 years
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vertos Medical: Vertos Medical offers the mild Procedure, a minimally invasive interventional treatment for lumbar spinal stenosis that targets chronic low back and leg pain. Like Relievant, it is a device-based interventional pain company focused on outpatient, implant-free procedures for chronic low back pain patients who have failed conservative care.
• SI-BONE: SI-BONE develops minimally invasive solutions for sacroiliac joint dysfunction, a major contributor to chronic low back pain. It is comparable to Relievant as a specialty interventional spine company that commercializes a single, procedurally distinct, FDA-cleared implant/procedure system through trained-physician networks.
• PainTEQ: PainTEQ developed LinQ, a minimally invasive SI joint fusion procedure for chronic low back pain. It is directly comparable to Relievant as a single-product interventional pain company commercializing a minimally invasive, outpatient procedure through specialist networks.
• Nevro: Nevro markets HF10 therapy, a high-frequency spinal cord stimulation system for chronic pain, including intractable low back and leg pain. It is comparable to Relievant as a neuromodulation-based interventional pain company competing for the same refractory chronic low back pain patient population.

Broad incumbents

• Medtronic: Medtronic operates a broad Pain Therapies and Spine portfolio including spinal cord stimulation, targeted drug delivery, and intervertebral devices for chronic pain. It is comparable to Relievant as a large incumbent serving the same interventional pain and spine market with overlapping clinical customers.
• Abbott: Abbott's Neuromodulation division offers spinal cord stimulation and dorsal root ganglion stimulation systems for chronic pain. It competes with Relievant for the same refractory chronic low back pain patients via an alternative neuromodulation modality, while operating across many other medical device categories.
• Boston Scientific: Boston Scientific is Relievant's acquirer and parent company, and its Neuromodulation segment includes spinal cord stimulation and radiofrequency ablation products for chronic pain. It is comparable as the broader portfolio incumbent whose pain franchise now encompasses the Intracept Procedure.
• Stryker: Stryker's Spine division and its 2024 acquisition of PainTEQ position it as a major interventional spine and chronic pain player. It is comparable to Relievant as a diversified medical device incumbent with growing interventional pain capabilities targeting chronic low back pain.

Emerging players

• Saluda Medical: Saluda Medical is developing closed-loop spinal cord stimulation systems for chronic pain, including chronic low back pain. It is comparable to Relievant as an emerging interventional pain neuromodulation company competing for similar refractory patients with novel neurostimulation technology.
• Stimwave Technologies: Stimwave developed wireless, injectable peripheral nerve stimulation and spinal cord stimulation devices for chronic pain management. It is comparable to Relievant as a niche neuromodulation innovator pursuing minimally invasive, outpatient solutions for chronic pain patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/RelievantMed
• LinkedInlinkedin.com/company/relievant-medsystems-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Relievant Medsystems